Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

391 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Role of circumferential margin involvement in the local recurrence of rectal cancer.
Adam IJ, Mohamdee MO, Martin IG, Scott N, Finan PJ, Johnston D, Dixon MF, Quirke P. Adam IJ, et al. Lancet. 1994 Sep 10;344(8924):707-11. doi: 10.1016/s0140-6736(94)92206-3. Lancet. 1994. PMID: 7915774
Unlocking the archive--gene expression in paraffin-embedded tissue.
Lewis F, Maughan NJ, Smith V, Hillan K, Quirke P. Lewis F, et al. J Pathol. 2001 Sep;195(1):66-71. doi: 10.1002/1096-9896(200109)195:1<66::AID-PATH921>3.0.CO;2-F. J Pathol. 2001. PMID: 11568892 Review.
Expression of DNA double-strand break repair proteins ATM and BRCA1 predicts survival in colorectal cancer.
Grabsch H, Dattani M, Barker L, Maughan N, Maude K, Hansen O, Gabbert HE, Quirke P, Mueller W. Grabsch H, et al. Clin Cancer Res. 2006 Mar 1;12(5):1494-500. doi: 10.1158/1078-0432.CCR-05-2105. Clin Cancer Res. 2006. PMID: 16533773
EphB2 is a prognostic factor in colorectal cancer.
Jubb AM, Zhong F, Bheddah S, Grabsch HI, Frantz GD, Mueller W, Kavi V, Quirke P, Polakis P, Koeppen H. Jubb AM, et al. Clin Cancer Res. 2005 Jul 15;11(14):5181-7. doi: 10.1158/1078-0432.CCR-05-0143. Clin Cancer Res. 2005. PMID: 16033834
Patients whose tumor stained 2+ for EphB2 expression (versus 0/1+) exhibited significantly prolonged overall survival: mean duration of survival, 2,514 versus 1,044 days; hazard ratio, 0.45; 95% confidence interval, 0.18 to 0.95 (P = 0.035). ...
Patients whose tumor stained 2+ for EphB2 expression (versus 0/1+) exhibited significantly prolonged overall survival: mean duration of surv …
Prediction of the response of colorectal cancer to systemic therapy.
Adlard JW, Richman SD, Seymour MT, Quirke P. Adlard JW, et al. Lancet Oncol. 2002 Feb;3(2):75-82. doi: 10.1016/s1470-2045(02)00648-4. Lancet Oncol. 2002. PMID: 11902527 Review.
Evidence of the oncologic superiority of cylindrical abdominoperineal excision for low rectal cancer.
West NP, Finan PJ, Anderin C, Lindholm J, Holm T, Quirke P. West NP, et al. J Clin Oncol. 2008 Jul 20;26(21):3517-22. doi: 10.1200/JCO.2007.14.5961. Epub 2008 Jun 9. J Clin Oncol. 2008. PMID: 18541901

Greater distance was observed from the muscularis propria or internal sphincter to the anterior, posterior, and lateral resection margins (all P < .0001). This was associated with lower circumferential resection margin (CRM) involvement (14.8% v 40.6%; P = .013)

Greater distance was observed from the muscularis propria or internal sphincter to the anterior, posterior, and lateral resection margins (a …
Identification of 42 Genes Linked to Stage II Colorectal Cancer Metastatic Relapse.
Al-Temaimi RA, Tan TZ, Marafie MJ, Thiery JP, Quirke P, Al-Mulla F. Al-Temaimi RA, et al. Int J Mol Sci. 2016 Apr 28;17(5):598. doi: 10.3390/ijms17050598. Int J Mol Sci. 2016. PMID: 27136531 Free PMC article.
HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials.
Richman SD, Southward K, Chambers P, Cross D, Barrett J, Hemmings G, Taylor M, Wood H, Hutchins G, Foster JM, Oumie A, Spink KG, Brown SR, Jones M, Kerr D, Handley K, Gray R, Seymour M, Quirke P. Richman SD, et al. J Pathol. 2016 Mar;238(4):562-70. doi: 10.1002/path.4679. Epub 2016 Jan 29. J Pathol. 2016. PMID: 26690310 Free PMC article.
HER2-overexpression was associated with KRAS/BRAF wild-type (WT) status at all stages: in 5.2% WT versus 1.0% mutated tumours (p < 0.0001) in stage IV and 2.1% versus 0.2% in stage II-III tumours (p = 0.01), respectively. ...
HER2-overexpression was associated with KRAS/BRAF wild-type (WT) status at all stages: in 5.2% WT versus 1.0% mutated tumours (p < …
391 results
Jump to page
Feedback